{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/","result":{"pageContext":{"chapter":{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD","depth":2,"htmlHeader":"<!-- begin field 79953265-5098-4bc8-8f79-a7810088fe78 --><h2>Scenario: Antiplatelet treatment for secondary prevention of cardiovascular disease (CVD)</h2><!-- end field 79953265-5098-4bc8-8f79-a7810088fe78 -->","summary":"Covers when to prescribe antiplatelet drugs in a person who has had a prior cardiovascular event (for example, myocardial infarction or stroke), which antiplatelet drug to prescribe, the management of gastrointestinal adverse effects caused by antiplatelet drugs and high blood pressure.","htmlStringContent":"<!-- begin item c81bf9ec-43d5-48c7-89d7-a7810088fd62 --><!-- begin field 657e13d0-569e-4395-b40c-acbc01567736 --><p>From age 16 years onwards.</p><!-- end field 657e13d0-569e-4395-b40c-acbc01567736 --><!-- end item c81bf9ec-43d5-48c7-89d7-a7810088fd62 -->","topic":{"id":"86dfa76b-bc1a-5d4b-bf7c-018d5d031947","topicId":"a68e1521-d84e-4abb-bb17-6186ba7a891a","topicName":"Antiplatelet treatment","slug":"antiplatelet-treatment","lastRevised":"Last revised in August 2020","chapters":[{"id":"af85e41e-4007-5daa-bc95-35aa03621ea0","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"db8ef934-0123-530e-9f34-52d23ea99e56","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"ebaf9360-bb92-51bc-8aba-ac3293fa1416","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"b34f13e6-85f8-5c85-b2f7-5678c0779a07","slug":"changes","fullItemName":"Changes"},{"id":"9532ea0d-f7f7-5a08-9076-dedbf78ca97d","slug":"update","fullItemName":"Update"}]},{"id":"0370616e-85d0-5654-b5ad-ea9980ad8eaa","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"24bebba9-1157-505c-834d-bf255dd856a9","slug":"goals","fullItemName":"Goals"},{"id":"b1ab86f3-b045-5a24-b8ea-506ae6fa94c8","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"cb61b0c8-a7f6-5e31-af33-9c4ade31a493","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"19dcf0a2-d60c-5fe4-94b7-d902d7cc17f8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"758947ec-f9bc-59c9-a07f-663f738f5428","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"8c16356c-f5cf-54fc-99e8-ccc08af83ec7","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"30e0cacd-1816-520e-8f4a-aba760ce71f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"9e23a119-ae6d-5e11-9691-ed23c4016c39","slug":"definition","fullItemName":"Definition"},{"id":"2ef5b7fd-3211-5769-8a72-083d9f8c40c8","slug":"mechanism-of-action","fullItemName":"Mechanism of action"},{"id":"ef9f4561-2787-59c9-974b-b656929c553c","slug":"indications","fullItemName":"Indications"},{"id":"7692771a-8763-57f6-b4fe-d4711f820cfb","slug":"complications","fullItemName":"Complications"}]},{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","fullItemName":"Management","slug":"management","subChapters":[{"id":"81844a0f-b280-563a-b66c-4a5dba6e1e9c","slug":"primary-prevention-of-cvd","fullItemName":"Scenario: Primary prevention of CVD"},{"id":"c2fb4ffa-788d-5d77-a694-3e30c3008d35","slug":"secondary-prevention-of-cvd","fullItemName":"Scenario: Secondary prevention of CVD"}]},{"id":"85828cd6-6943-58a7-9657-71760be76497","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"d408bf47-147e-5914-ab35-c4142ec2a33e","slug":"low-dose-aspirin","fullItemName":"Low dose aspirin"},{"id":"4098d4bf-7db2-5e79-bdec-17a2bbfaca6a","slug":"clopidogrel","fullItemName":"Clopidogrel"},{"id":"d5d8e5ca-9f57-5ac9-955b-614b85700f3e","slug":"dipyridamole","fullItemName":"Dipyridamole"},{"id":"52159350-4f8e-536b-99c4-a75908d6233a","slug":"prasugrel","fullItemName":"Prasugrel"},{"id":"92100407-8f08-53c0-8df1-1e802f4dcbe9","slug":"ticagrelor","fullItemName":"Ticagrelor"}]},{"id":"ec007ae2-2b14-50b1-a091-3875c81c5adb","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"f54cfffb-be9e-5523-a47f-c1100845c9c4","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"4ce7f1c7-df35-54c7-9f8b-b1aefe5762f1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f4d603b9-b19a-53ac-8058-8c414be0a10b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"69fb4d5c-2946-5ef6-8c7f-b5f81dd52f9c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d1e16069-862f-500a-9f58-e84cb201da64","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"fab694fa-9176-5402-b7b5-729a22dd611f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3852e22b-c968-5afe-81be-ac1efce390da","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"d31d1a85-d8c2-5598-b7e0-e8b2da36e45c","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"f0228a85-9469-5e4c-8ffe-a2d4583ff90d","slug":"when-to-prescribe-antiplatelet-treatment","fullItemName":"When to prescribe antiplatelet treatment","depth":3,"htmlHeader":"<!-- begin field b22522a2-5cd5-4ab1-bf2b-a7810088fe7c --><h3>When should antiplatelet treatment be prescribed for secondary prevention of cardiovascular disease?</h3><!-- end field b22522a2-5cd5-4ab1-bf2b-a7810088fe7c -->","summary":null,"htmlStringContent":"<!-- begin item 057f77b6-177d-4761-b392-a7810088fe7c --><!-- begin field f5682592-6b6e-41d5-a783-a7810088fe7c --><ul><li>Antiplatelet treatment should be prescribed for the secondary prevention of cardiovascular events in people with:<ul><li>Acute coronary syndrome (ACS).</li><li>Angina.</li><li>Atrial fibrillation (AF) — in these people anticoagulants are more usually prescribed. </li><li>Peripheral arterial disease (PAD).</li></ul></li><li>Antiplatelet treatment should also be prescribed for the secondary prevention of cardiovascular events in people after:<ul><li>Myocardial infarction (MI).</li><li>Stent implantation.</li><li>Stroke or transient ischaemic attack (TIA).</li></ul></li><li>For further information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/angina/\">Angina</a>, <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>, <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a>.</li></ul><!-- end field f5682592-6b6e-41d5-a783-a7810088fe7c --><!-- end item 057f77b6-177d-4761-b392-a7810088fe7c -->","subChapters":[{"id":"200bdac1-884a-51e3-a219-03a09a408e5e","slug":"basis-for-recommendation-a0b","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field e971851f-2ee7-402b-b484-a7810088fe81 --><h4>Basis for recommendation</h4><!-- end field e971851f-2ee7-402b-b484-a7810088fe81 -->","summary":null,"htmlStringContent":"<!-- begin item a0b8f2ff-1ff4-4864-8a45-a7810088fe81 --><!-- begin field bb84f230-c7f7-470a-ada3-a7810088fe81 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016a</a>], <em>Unstable angina and NSTEMI: early management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013a</a>], <em>Transient ischaemic attack: clopidogrel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013c</a>], <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013b</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guidelines <em>Antithrombotics: indications and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2013</a>] and <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2018</a>], and the European Society of Cardiology (ECS)<em> 2016 European Guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>]. </p><!-- end field bb84f230-c7f7-470a-ada3-a7810088fe81 --><!-- end item a0b8f2ff-1ff4-4864-8a45-a7810088fe81 -->","subChapters":[]}]},{"id":"b643a6aa-c48a-52ea-9adc-6be669229c39","slug":"which-antiplatelet-treatment","fullItemName":"Which antiplatelet treatment","depth":3,"htmlHeader":"<!-- begin field bee4a844-9963-4cfc-b1a7-a781008a0690 --><h3>Which antiplatelet treatment should I prescribe for secondary prevention of cardiovascular disease?</h3><!-- end field bee4a844-9963-4cfc-b1a7-a781008a0690 -->","summary":null,"htmlStringContent":"<!-- begin item 5bda44fb-0bea-4fd2-a3e9-a781008a055d --><!-- begin field afd8ccb1-461f-4029-bb21-a781008a0690 --><ul><li><strong>Angina </strong><ul><li>Consider prescribing aspirin 75 mg daily for people with stable angina, taking into account the risk of bleeding and comorbidities.</li><li>Offer aspirin 75 mg as soon as possible to all people with unstable angina and continue indefinitely, unless contraindicated by bleeding risk or aspirin hypersensitivity.<ul><li>For people in whom aspirin is contraindicated or not tolerated, consider clopidogrel 75 mg daily. </li></ul></li></ul></li><li><strong>Atrial fibrillation (AF)</strong><ul><li>Dual antiplatelet therapy (DAPT) of aspirin 75 mg daily and clopidogrel 75 mg daily may be suitable for people who are unable or unwilling to take anticoagulants. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>. </li></ul></li><li><strong>Acute coronary syndrome (ACS) </strong>which is medically managed (unstable angina, non-ST segment elevation myocardial infarction [NSTEMI] or ST-segment elevation myocardial infarction [STEMI]). <ul><li><strong>Prescribe DAPT </strong>— aspirin 75 mg daily plus ticagrelor 90 mg twice a day for 12 months. <ul><li>Ticagrelor is the preferred choice (even in those previously treated with clopidogrel) unless the bleeding risk outweighs the benefit.</li></ul></li><li>For people at high risk of bleeding, continue DAPT for at least one month. </li><li>For people with MI at high ischaemic risk who have tolerated DAPT without a bleeding complication, consider treatment with DAPT (ticagrelor 60 mg twice daily) in addition to aspirin for longer than 12 months and up to 36 months.<ul><li>If ticagrelor is not suitable, consider clopidogrel 75 mg daily (as well as aspirin) for longer than 12 months.</li></ul></li></ul></li><li><strong>Percutaneous coronary intervention (PCI)</strong>.<ul><li><strong>For people with ACS who are undergoing PCI</strong>, aspirin (75–100 mg) in combination with one of the following antiplatelets is initiated in secondary care:<ul><li>Prasugrel 10 mg daily (or 5 mg daily if the person weighs less than 60 kg, or if the person is 75 years of age or older).</li><li>Ticagrelor 90 mg twice a day.</li><li>Clopidogrel 75 mg daily (if prasugrel or ticagrelor are not suitable).</li></ul></li><li>This treatment is usually continued for up to 12 months after the procedure, then aspirin is continued alone.<ul><li>For people at high risk of bleeding complications, stop DAPT after 6 months and continue aspirin alone. Prasugrel is not recommended.</li><li>For people who have tolerated DAPT without a bleeding complication, consider continuing DAPT for longer than 12 months, up to 36 months. Ticagrelor 60 mg twice daily is the preferred option. </li></ul></li><li><strong>For people with stable coronary artery disease who are undergoing PCI</strong>, aspirin 75 mg daily with clopidogrel 75 mg daily is initiated in secondary care and continued for 6 months.<ul><li>Ticagrelor, or prasugrel may be considered instead of clopidogrel where appropriate.</li><li>For people at high risk of bleeding, continue DAPT for 3 months.</li><li>For people in whom 3 months of DAPT poses safety concerns, consider stopping DAPT after 1 month.</li><li>For people who have tolerated DAPT without a bleeding complication, consider continuing DAPT for longer than 6 months, up to 36 months. </li></ul></li></ul></li><li><strong>Coronary artery bypass grafting (CABG) — in people undergoing CABG antiplatelet treatment will be managed by specialists.</strong><ul><li>People treated with DAPT who then undergo CABG should continue DAPT when it is safe to do so after surgery, and continue until the recommended duration of therapy is complete.</li></ul></li><li><strong>Stroke, or transient ischaemic attack (TIA)</strong><ul><li>Clopidogrel 75 mg daily is the preferred antiplatelet medication. </li><li>If clopidogrel is contraindicated or not tolerated, give modified–release dipyridamole (200 mg twice a day) combined with low dose aspirin.</li><li>If both clopidogrel and modified-release dipyridamole are contraindicated or not tolerated, give aspirin alone.</li><li>If both clopidogrel and aspirin are contraindicated or not tolerated, give modified-release dipyridamole alone.</li><li><strong>Note: </strong>Prasugrel should not be given to people with a history of stroke or TIA. </li></ul></li><li><strong>Peripheral arterial disease (PAD), or multivascular disease </strong><ul><li>Clopidogrel 75 mg daily is the preferred antiplatelet medication. </li><li>If clopidogrel is contraindicated or not tolerated, give low dose aspirin alone.</li></ul></li></ul><!-- end field afd8ccb1-461f-4029-bb21-a781008a0690 --><!-- end item 5bda44fb-0bea-4fd2-a3e9-a781008a055d -->","subChapters":[{"id":"7568929e-b68b-520e-947a-22303f7fedf2","slug":"basis-for-recommendation-938","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field f897f1df-e5c9-4750-831f-a781008a0695 --><h4>Basis for recommendation</h4><!-- end field f897f1df-e5c9-4750-831f-a781008a0695 -->","summary":null,"htmlStringContent":"<!-- begin item 9387e7c6-ff6f-4ead-92b9-a781008a0695 --><!-- begin field 5f99c9db-2d3a-405c-afac-a781008a0695 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2010a</a>], <em>Myocardial infarction: cardiac rehabilitation and prevention of further cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013b</a>], <em>Unstable angina and NSTEMI: early management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013a</a>], <em>Atrial fibrillation: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014a</a>], NICE technology appraisals <em>Ticagrelor for preventing atherothrombotic events after myocardial infarction</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016b</a>], and <em>Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014b</a>], the NICE evidence summary <em>Transient ischaemic attack: clopidogrel</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2013c</a>], the Scottish Intercollegiate Guidelines Network (SIGN) guidelines <em>Risk estimation and the prevention of cardiovascular disease </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2017</a>], <em>Prevention of stroke in patients with atrial fibrillation</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2014</a>], and <em>Management of stable angina </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2018</a>], the Royal College of Physicians (RCP) <em>National clinical guideline for stroke</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">RCP, 2016</a>], the European Society of Cardiology (ESC) <em>2016 European Guidelines on cardiovascular disease prevention in clinical practice</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>], the <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>], <em>2017 ESC Guidelines on the diagnosis and treatment of peripheral arterial diseases </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018b</a>], the Canadian Cardiovascular Society (CCS) guideline <em>2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">CCS, 2018</a>], the American Heart Association (AHA) and American College of Cardiology (ACC) <em>2016 AHA/ACC Guideline on the management of patients with lower extremity peripheral artery disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">AHA, 2017</a>], and the Summary of Product Characteristics for aspirin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017a</a>], clopidogrel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>], prasugrel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>], and ticagrelor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>]. </p><h5>Antiplatelet therapy in atrial fibrillation (AF)</h5><ul><li>Antiplatelet therapy should only be considered for people with AF when warfarin or one of the newer anticoagulants has been declined [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2014</a>]. </li><li>Aspirin monotherapy should not be used solely for stroke prevention in people with AF [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014a</a>]. </li><li>Clopidogrel is licensed for use in combination with aspirin for people with AF in whom anticoagulants are unsuitable [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>].  </li></ul><h5>Clopidogrel use in transient ischaemic attack (TIA) and stroke</h5><ul><li>Aspirin plus modified-release dipyridamole and clopidogrel monotherapy are equally effective, with both options superior to aspirin monotherapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">RCP, 2016</a>]. </li><li>NICE recommends clopidogrel as the most cost-effective antiplatelet for secondary prevention of stoke [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2010a</a>], however, clopidogrel is not licensed for use after a TIA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>], so NICE recommends treatment with modified-release dipyridamole plus aspirin as the preferred treatment option for TIA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2010a</a>]. </li><li>However, the RCP considers that a unified approach to the treatment of TIA and ischaemic stroke is more appropriate and recommends clopidogrel as the preferred option for people who have had a TIA, as the benefits of using it first-line outweigh the disadvantages [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">RCP, 2016</a>].  </li><li>ESC recommends aspirin alone, dipyridamole plus aspirin, or clopidogrel alone for people with non-cardioembolic ischaemic stroke or TIA [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2016</a>]. </li></ul><h5>Low dose aspirin </h5><ul><li>The optimal dose range of aspirin in people treated with dual antiplatelet therapy (DAPT) that provides maximal protection from ischaemic events and minimizes bleeding risk appears to be 75–100 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]. </li><li>People taking prasugrel should also take aspirin 75-325 mg daily [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014b</a>]. </li><li>Ticagrelor should always be given with aspirin 75-100 mg [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2016b</a>]. </li></ul><h5>Prasugrel and high risk of bleeding</h5><ul><li>ESC does not recommend the use of prasugrel in people at high risk of bleeding who have undergone percutaneous coronary intervention (PCI)<strong> </strong>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]. </li><li>The use of prasugrel in people at increased risk of bleeding should only be considered when the benefits in terms of prevention of ischaemic events are deemed to outweigh the risk of serious bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>]. </li></ul><h5>Duration of treatment after PCI </h5><ul><li>ESC recommends that DAPT can be continued for up to 30 months in people with stable coronary artery disease that have undergone PCI, and that for people with ACS who undergo PCI, treatment can be continued beyond 12 months, but does not specify a maximum duration of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>].  </li><li>However, a Canadian guideline recommends that it in both scenarios, DAPT can be continued for up to 36 months [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">CCS, 2018</a>]. </li><li>CKS recommends using clinical judgement to determine the appropriate duration of DAPT taking into account the potential benefits and the individual's risk of bleeding.</li></ul><!-- end field 5f99c9db-2d3a-405c-afac-a781008a0695 --><!-- end item 9387e7c6-ff6f-4ead-92b9-a781008a0695 -->","subChapters":[]}]},{"id":"1437dd3b-f4e7-50fa-8dec-6ec967f7010e","slug":"preventing-dyspepsia","fullItemName":"Preventing dyspepsia","depth":3,"htmlHeader":"<!-- begin field 71adf240-4b52-4c5f-a148-a781008a2b84 --><h3>How can I help prevent dyspepsia?</h3><!-- end field 71adf240-4b52-4c5f-a148-a781008a2b84 -->","summary":null,"htmlStringContent":"<!-- begin item 9e89d085-43ef-4858-b5c4-a781008a2a75 --><!-- begin field a7c5e577-8d53-4caf-9ed3-a781008a2b84 --><ul><li>If the person is taking a dose of aspirin higher than 75 mg daily, reduce the dose to 75 mg daily (unless a higher dose is indicated) to be taken after food.<ul><li>Do not prescribe enteric coated aspirin.</li></ul></li><li>Provide general advice to help reduce gastrointestinal (GI) adverse effects. For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-unidentified-cause/management/dyspepsia-unidentified-cause/#initial-management\">Initial management</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-unidentified-cause/\">Dyspepsia - unidentified cause</a>. </li><li>Consider testing for and treating <em>Helicobacter pylori</em> if the person has a history of ulcer disease or upper GI bleeding, unless previously tested and treated for this.</li><li><strong>If the person has a <a class=\"topic-reference internal-reference\" href=\"/topics/antiplatelet-treatment/management/secondary-prevention-of-cvd/#high-risk-of-gi-adverse-effects\">high risk</a> of GI adverse effects (for example, bleeding) and is taking: </strong><ul><li><strong>Low-dose aspirin alone, or in combination with ticagrelor or prasugrel:</strong><ul><li>Co-prescribe a proton pump inhibitor (PPI), such as lansoprazole, omeprazole, or pantoprazole, for gastroprotection.</li><li>For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/management/nsaids-prescribing-issues/#proton-pump-inhibitor-doses-for-gastroprotection\">Licensed doses of proton pump inhibitors used for gastroprotection for people who require continued NSAID treatment</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/nsaids-prescribing-issues/\">NSAIDs - prescribing issues</a>. </li></ul></li><li><strong>Clopidogrel alone, or in combination with low-dose aspirin:</strong><ul><li>Co-prescribe a PPI, except omeprazole or esomeprazole.</li></ul></li></ul></li></ul><!-- end field a7c5e577-8d53-4caf-9ed3-a781008a2b84 --><!-- end item 9e89d085-43ef-4858-b5c4-a781008a2a75 -->","subChapters":[{"id":"521e0b83-3fc6-5c8d-a9fa-b7d40d77e8ee","slug":"high-risk-of-gi-adverse-effects","fullItemName":"High risk of GI adverse effects","depth":4,"htmlHeader":"<!-- begin field 9fcba2f6-3e52-419d-8d70-a781008c38de --><h4>People at high risk of GI adverse effects</h4><!-- end field 9fcba2f6-3e52-419d-8d70-a781008c38de -->","summary":null,"htmlStringContent":"<!-- begin item c425681f-7d45-49fa-a29c-a781008c37f1 --><!-- begin field 08750d15-001a-4e62-b1f6-a781008c38de --><ul><li><strong>People are at high risk of gastrointestinal (GI) adverse effects with antiplatelet treatment if the following risk factors are present:</strong><ul><li>High dose of aspirin.</li><li>Older age, especially aged over 70 years.</li><li>History of gastroduodenal ulcer, GI bleeding, or gastroduodenal perforation.</li><li><em>Helicobacter pylori</em> infection.</li><li>Concomitant use of medicines that are known to increase the risk of GI bleeds.</li></ul></li></ul><p><strong>Table 1.</strong> Examples of common medicines known to cause GI bleeding or ulceration.</p><table><thead><tr><th>Therapy Group</th><th>Examples</th></tr></thead><tbody><tr><td>Antiplatelets</td><td>Aspirin, clopidogrel, prasugrel</td></tr><tr><td>Antidepressants — selective serotonin-reuptake inhibitors (SSRIs)</td><td>Citalopram, fluoxetine, paroxetine</td></tr><tr><td>Anticoagulants</td><td>Warfarin, dabigatran, apixaban, rivaroxaban</td></tr><tr><td>Corticosteroids</td><td>Prednisolone</td></tr><tr><td>Nonsteroidal anti-inflammatory drugs (NSAIDs)</td><td>Aspirin, ibuprofen, diclofenac, naproxen, indometacin</td></tr><tr><td>Potassium-channel activator</td><td>Nicorandil†</td></tr><tr><td colspan=\"2\">† Nicorandil is associated with a risk of gastrointestinal ulceration, including perianal ulceration. Ulcers that result from nicorandil are refractory to treatment, including surgery; they respond only to withdrawal of nicorandil.</td></tr><tr><td colspan=\"2\"><strong>Data from:</strong> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">BNF 75, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">MHRA, 2016</a>]</td></tr></tbody></table><!-- end field 08750d15-001a-4e62-b1f6-a781008c38de --><!-- end item c425681f-7d45-49fa-a29c-a781008c37f1 -->","subChapters":[]},{"id":"34ae9204-23e1-5dfe-88fc-4e448433fa0e","slug":"basis-for-recommendation-1c6","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 03d63369-85fb-4bc4-9994-a781008a2b8d --><h4>Basis for recommendation</h4><!-- end field 03d63369-85fb-4bc4-9994-a781008a2b8d -->","summary":null,"htmlStringContent":"<!-- begin item 1c6296a1-c337-4630-9edd-a781008a2b8d --><!-- begin field b1e07a80-5764-427b-b0cc-a781008a2b8d --><p>This information is based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Antithrombotics: indications and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2013</a>], the European Society of Cardiology (ESC) <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>], the American College of Cardiology Foundation consensus document <em>Reducing g</em><em>astrointestinal</em><em> risks of antiplatelet therapy and NSAID use</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>], the American College of Chest Physicians guideline <em>Antiplatelet drugs: antithrombotic therapy and prevention of thrombosis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Eikelboom et al, 2012</a>], the National Institute for Health and Care Excellence (NICE) guidelines <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014c</a>], Public Health England (PHE) quick reference guide <em>Test and treat for Helicobacter pylori (HP) in dyspepsia </em>recommends <em>H pylori </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">PHE, 2017</a>], and expert opinion in narrative reviews <em>Low-dose aspirin and upper gastrointestinal damage: epidemiology, prevention and treatment</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas and Scheiman, 2007</a>], and <em>Management of low-dose aspirin and clopidogrel in clinical practice: a gastrointestinal perspective</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>].</p><h5>Low dose aspirin </h5><ul><li>There is evidence that the gastrointestinal (GI) adverse effects of aspirin are dose-dependent. Doses of less than 300 mg daily are associated with fewer GI adverse effects than 1,200 mg daily, and doses of 100 mg or less are associated with even fewer adverse effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Eikelboom et al, 2012</a>].</li><li>To minimise the risk of bleeding, the lowest recommended dose of aspirin should be used for the clinical indication [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SIGN, 2013</a>]. <ul><li>The standard dose of aspirin for thromboprophylaxis is 75 mg daily.</li></ul></li><li>In people treated with dual antiplatelet therapy (DAPT), a daily aspirin dose of 75–100 mg is recommended [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]. </li></ul><h5>Enteric-coated aspirin </h5><ul><li>Enteric-coated aspirin does not reduce the risk of GI complications, as the main effect of aspirin on the gastric mucosa depends on the systemic effects rather than the local topical effects [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>].</li></ul><h5>Testing for <em>H. pylori</em> infection</h5><ul><li><em>H. pylori</em> infection is associated with an increased risk of duodenal damage in people taking low dose aspirin, and eradication of <em>H. pylori</em> in people with GI ulcers or bleeding is associated with a reduction in the occurrence of upper GI complications, both in non-aspirin and aspirin users [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas and Scheiman, 2007</a>]. </li><li>In people taking low dose aspirin without a history of peptic ulcer, the role of <em>H. pylori</em> eradication is controversial and few data are available [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>]. </li><li>The Public Health England quick reference guide <em>Test and treat for Helicobacter pylori (HP) in dyspepsia </em>recommends <em>H. pylori </em>testing for people with a history of gastric or duodenal ulcer/bleed who have not previously been tested, and for people before taking NSAIDs if they have a prior history of gastro-duodenal ulcers/bleeds [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">PHE, 2017</a>]. </li><li>Testing for and eradicating <em>H. pylori</em> in people with a history of ulcer disease is recommended before starting chronic antiplatelet therapy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>]. </li></ul><h5>Use of PPIs with antiplatelets </h5><ul><li>GI haemorrhage is the most common serious bleeding complication from the use of long-term antiplatelet therapy. Randomized controlled trials (RCTs) have shown that proton pump inhibitors (PPIs) reduce the rate of recurrent Gl bleeding in high-risk people receiving aspirin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]. <ul><li>There are no RCTs comparing use versus non-use of PPIs in people taking aspirin plus prasugrel, or aspirin plus ticagrelor. However, the risk of GI bleeding is higher in people taking prasugrel or ticagrelor as part of DAPT, compared to clopidogrel.</li></ul></li><li>PPIs are the preferred option to reduce GI adverse effects in people taking low dose aspirin, as the level of suppression provided by traditional doses of H2-receptor antagonists does not prevent NSAID related ulcers [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>]. </li><li>PPIs are more effective than H2-receptor antagonists as gastroprotective agents in people taking antiplatelets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>].</li><li>Clopidogrel should not be used alone as an alternative to low dose aspirin, or low dose aspirin plus PPI in people with high risk of GI adverse effects risk to reduce the risk of GI bleeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>]  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>].   </li></ul><h5>Choice of PPI </h5><ul><li>A possible interaction between clopidogrel and PPIs, particularly omeprazole and esomeprazole, may lead to reduced antiplatelet effects when taken concurrently [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>].   <ul><li>Pantoprazole and rabeprazole have the lowest effect. </li><li>No significant interaction occurs when PPIs are taken concurrently with prasugrel or ticagrelor.  </li></ul></li><li>Consider PPIs other than omeprazole or esomeprazole in patients who are taking clopidogrel. Other Gl therapy such as H2 blockers (except cimetidine) or antacids may be more suitable in some people [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">MHRA, 2010</a>].  </li></ul><h5>PPI doses</h5><ul><li>Higher daily doses of PPIs lead to greater levels of acid suppression, however, data do not support the need for more than standard once-daily dosing of PPIs for people taking low dose aspirin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>]. </li></ul><h5>Risk factors for GI adverse effects</h5><ul><li>Severe comorbidities may also be a risk factor for GI adverse effects in people taking antiplatelets, however, the evidence for this is conflicting [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Lanas, 2015</a>].  </li></ul><!-- end field b1e07a80-5764-427b-b0cc-a781008a2b8d --><!-- end item 1c6296a1-c337-4630-9edd-a781008a2b8d -->","subChapters":[]}]},{"id":"768fc90e-1f5c-5cd7-a70a-dbd1be23dc44","slug":"managing-antiplatelet-induced-dyspepsia","fullItemName":"Managing antiplatelet-induced dyspepsia","depth":3,"htmlHeader":"<!-- begin field ec7eb0cf-640a-4f4f-b5b2-a781008a57a8 --><h3>How should I manage antiplatelet-induced dyspepsia?</h3><!-- end field ec7eb0cf-640a-4f4f-b5b2-a781008a57a8 -->","summary":null,"htmlStringContent":"<!-- begin item 16035f85-00fe-4c4f-bb56-a781008a56c1 --><!-- begin field eaa7b7a4-9530-4595-a1b4-a781008a57a8 --><ul><li><strong>In people with alarm features, refer urgently </strong><strong>using a suspected cancer pathway referral (for an appointment within 2 weeks).</strong><ul><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/gastrointestinal-tract-upper-cancers-recognition-referral/\">Gastrointestinal tract (upper) cancers - recognition and referral</a>. </li><li>While waiting for endoscopy, consider stopping antiplatelet treatment if appropriate, or prescribe a simple antacid to relieve dyspepsia (as proton pump inhibitors [PPIs] and H2-receptor antagonists should be avoided for at least 2 weeks before endoscopy).<ul><li>Do not stop antiplatelet treatment for people at very high cardiovascular risk without seeking specialist advice (for example, after an episode of acute coronary syndrome or stroke/transient ischaemic attack, or after a percutaneous coronary intervention).</li></ul></li></ul></li><li><strong>In people without alarm features:</strong><ul><li>Ensure that general measures to reduce the risk of gastrointestinal (GI) adverse effects have been taken. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-unidentified-cause/\">Dyspepsia - unidentified cause</a>. </li><li>Prescribe an antacid or an alginate to use 'as required' for relief of dyspeptic symptoms.</li><li>If taking low-dose aspirin consider treatment with a full-dose PPI for 1 month or test and treat for <em>Helicobacter pylori</em> (if the person's status is unknown).<ul><li>For information on testing for and treating <em>H. pylori</em> as well as prescribing PPIs, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/dyspepsia-unidentified-cause/\">Dyspepsia - unidentified cause</a>.</li></ul></li><li>If symptoms recur after PPI treatment or eradication treatment, prescribe the lowest dose of PPI to control symptoms.</li><li>Review maintenance treatment at least annually.</li></ul></li><li><strong>If taking clopidogrel alone or in combination with aspirin:</strong><ul><li>Avoid co-prescribing omeprazole or esomeprazole with clopidogrel — use an alternative PPI, or consider prescribing an H2-receptor antagonist (H2RA) for 1 month (for example, ranitidine [avoid cimetidine]).</li></ul></li><li><strong>Refer</strong> to secondary care for investigation if symptoms persist despite treatment.</li></ul><!-- end field eaa7b7a4-9530-4595-a1b4-a781008a57a8 --><!-- end item 16035f85-00fe-4c4f-bb56-a781008a56c1 -->","subChapters":[{"id":"379dc417-61a0-5e38-a5be-421501403604","slug":"basis-for-recommendation-78f","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 34758e48-fd99-4df7-85a3-a781008a57a8 --><h4>Basis for recommendation</h4><!-- end field 34758e48-fd99-4df7-85a3-a781008a57a8 -->","summary":null,"htmlStringContent":"<!-- begin item 78fcf485-9612-435e-ae33-a781008a57a8 --><!-- begin field 7391f042-634d-4cd6-8543-a781008a57a8 --><p>CKS could find no guidelines on managing dyspepsia in people taking antiplatelet medication. These recommendations are extrapolated from the National Institute for Health and Care Excellence (NICE) guideline <em>Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">NICE, 2014c</a>], and what CKS considers good clinical practice.</p><h5>Basis for testing for and treating <em>Helicobacter pylori</em></h5><ul><li>Although testing for and eradicating <em>H pylori</em> in people with a history of ulcer disease is recommended before starting long-term antiplatelet treatment, CKS identified no guidelines on the role of <em>H. pylori </em>eradication in managing dyspepsia in people receiving low-dose aspirin.</li><li><em>H. pylori</em> infection is an important and independent risk factor for ulcer and gastrointestinal bleeding in people taking low dose aspirin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">Bhatt et al, 2008</a>].</li></ul><!-- end field 7391f042-634d-4cd6-8543-a781008a57a8 --><!-- end item 78fcf485-9612-435e-ae33-a781008a57a8 -->","subChapters":[]}]},{"id":"93eb4d3f-1c9c-569d-b1ec-b7f0ac31f8a2","slug":"switching-antiplatelets","fullItemName":"Switching antiplatelets","depth":3,"htmlHeader":"<!-- begin field 98b4e11f-f698-488c-9e06-a8f8008a1d92 --><h3>How should I manage switching of antiplatelet treatments?</h3><!-- end field 98b4e11f-f698-488c-9e06-a8f8008a1d92 -->","summary":null,"htmlStringContent":"<!-- begin item 639f60b5-5e08-48a0-a378-a8f8008a14fc --><!-- begin field 22d61229-389f-499e-a374-a8f8008a1d92 --><ul><li>Switching between antiplatelet medication may be required, if the current treatment is unsuitable.</li><li>If switching from clopidogrel to:<ul><li>Ticagrelor — start 90 mg twice daily, 24 hours after the last clopidogrel dose.</li><li>Prasugrel — start 10 mg daily, 24 hours after last clopidogrel dose. </li></ul></li><li>If switching from prasugrel to:<ul><li>Clopidogrel — start 75 mg daily, 24 hours after the last prasugrel dose.</li><li>Ticagrelor — start 90 mg twice daily, 24 hours after the last prasugrel dose. </li></ul></li><li>If switching from ticagrelor to:<ul><li>Clopidogrel — give a loading dose of 600 mg, 24 hours after the last ticagrelor dose. Then continue with 75 mg daily.</li><li>Prasugrel — give a 60 mg loading dose, 24 hours after the last ticagrelor dose. Then continue with 10 mg daily.</li></ul></li></ul><!-- end field 22d61229-389f-499e-a374-a8f8008a1d92 --><!-- end item 639f60b5-5e08-48a0-a378-a8f8008a14fc -->","subChapters":[{"id":"97da8630-6004-54fe-bf4d-0950b44a134e","slug":"basis-for-recommendation-9ff","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 39828307-12a8-4f54-a650-a8f8008a1e2c --><h4>Basis for recommendation</h4><!-- end field 39828307-12a8-4f54-a650-a8f8008a1e2c -->","summary":null,"htmlStringContent":"<!-- begin item 9ff4f7b5-26b6-4e9b-8fbc-a8f8008a1e2c --><!-- begin field 7eaba05b-a931-4755-b97c-a8f8008a1e2c --><p>These recommendations are based on the European Society of Cardiology (ESC) guideline <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>].</p><!-- end field 7eaba05b-a931-4755-b97c-a8f8008a1e2c --><!-- end item 9ff4f7b5-26b6-4e9b-8fbc-a8f8008a1e2c -->","subChapters":[]}]},{"id":"8b0a39c0-a1b4-5a3b-8c43-e1f966858480","slug":"surgery-dental-treatment","fullItemName":"Surgery and dental treatment","depth":3,"htmlHeader":"<!-- begin field 20a30c91-8764-4549-b49c-a8f8008ab842 --><h3>How should I manage people taking antiplatelets who are undergoing surgery or dental treatment?</h3><!-- end field 20a30c91-8764-4549-b49c-a8f8008ab842 -->","summary":null,"htmlStringContent":"<!-- begin item 78a27cf2-1965-4396-aad0-a8f8008ab676 --><!-- begin field b712d258-fc45-4b2d-ba91-a8f8008ab842 --><ul><li>Advise people taking antiplatelet medications to inform dentists or medical teams before any surgery is scheduled. </li><li>Dual antiplatelet therapy (DAPT) increases the risk of surgical bleeding complications. <ul><li>The bleeding risk is further increased if ticagrelor or prasugrel are used rather than clopidogrel.</li></ul></li><li>For people undergoing dental surgery antiplatelet therapy should continue uninterrupted.</li><li>For people undergoing coronary artery bypass grafting (CABG), discontinue:<ul><li>Ticagrelor 3–7 days before surgery.</li><li>Clopidogrel 5–7 days before surgery.</li><li>Prasugrel  at least 7 days before surgery.</li></ul></li><li>For people undergoing non-cardiac surgery, the risk of bleeding and thrombosis should be considered by the specialist team.</li></ul><!-- end field b712d258-fc45-4b2d-ba91-a8f8008ab842 --><!-- end item 78a27cf2-1965-4396-aad0-a8f8008ab676 -->","subChapters":[{"id":"dd4a4744-5022-5e77-a39f-a675e1a994fc","slug":"basis-for-recommendation-7b8","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 6c719902-8f9c-4a05-8f85-a8f8008ab856 --><h4>Basis for recommendation</h4><!-- end field 6c719902-8f9c-4a05-8f85-a8f8008ab856 -->","summary":null,"htmlStringContent":"<!-- begin item 7b8e2555-52bc-45fb-9b16-a8f8008ab856 --><!-- begin field fe54695e-3d15-4e8d-bfc0-a8f8008ab856 --><p>These recommendations are based on the European Society of Cardiology (ESC) <em>2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>], the Scottish Dental Clinical Effectiveness Programme (SDCEP) <em>Management of Dental Patients Taking Anticoagulants or Antiplatelet Drugs </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">SDCEP, 2015</a>], and the Summary of Product Characteristics for clopidogrel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>], ticagrelor [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>] and prasugrel [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>]. </p><ul><li>Continuation of dual antiplatlet therapy until coronary artery bypass grafting (CABG) increases the risk of excessive perioperative bleeding, transfusions, and re-exploration for bleeding. It is recommended that clopidogrel, ticagrelor or prasugrel are discontinued whenever possible before elective CABG [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>].  </li><li>The SPCs recommend that antiplatelets should be discontinued 7 days before surgery if antiplatlet effect is not desired [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2018a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ABPI, 2017b</a>].</li><li>However, ESC advises that for people undergoing CABG, the following discontinuation timings should be considered [<a class=\"bibliography-reference internal-reference\" href=\"/topics/antiplatelet-treatment/references/\">ESC, 2018a</a>]:   <ul><li>Ticagrelor — 3 days before surgery.</li><li>Clopidogrel — 5 days before surgery.  </li><li>Prasugrel — at least 7 days before surgery. </li></ul></li></ul><!-- end field fe54695e-3d15-4e8d-bfc0-a8f8008ab856 --><!-- end item 7b8e2555-52bc-45fb-9b16-a8f8008ab856 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}